Hemogenyx Raises £291,665 Through Warrant Exercises

Hemogenyx Pharmaceuticals plc (LSE:
HEMO) said on 3 September 2026 that holders exercised warrants for 96,825 new ordinary shares.

The exercises were completed at prices ranging from 180p to 350p per share, generating £291,665 in gross proceeds for the clinical-stage biotech company.

The new shares are expected to be admitted to the FCA Official List and London Stock Exchange Main Market at 8:
00 a.m. on 8 September 2026.

Following admission, Hemogenyx expects to have 6,896,786 ordinary shares in issue, each carrying one voting right. The shares rank equally with its existing ordinary shares.

The transaction modestly increases the share count while bringing additional cash into the company; it is a warrant exercise rather than a newly announced equity placing.